Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans with Alcohol Use Disorder: A Randomized Pilot Proof‐of‐Concept Study
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background: Injectable naltrexone for alcohol use disorders (AUDs) has been efficacious in several studies. It has not been (i) compared head‐to‐head with oral naltrexone or (ii) examined in the hospital setting as an intervention that might facilitate treatment attendance after hospital discharge. Methods: Fifty‐four hospitalized veterans identified as having DSM‐IV‐TR alcohol dependence were randomized to receive (i) a 50 mg oral naltrexone plus a 30‐day prescription or (ii) a 380 mg intramuscular naltrexone injection prior to discharge. Of 113 veteran inpatients deemed eligible based on screening criteria, 54 met final eligibility criteria and were enrolled and randomized. Baseline data included demographics, alcohol consumption, and comorbidity. Measures of treatment initiation and engagement and alcohol consumption were reassessed at 14‐ and 45‐day follow‐ups. Results: Thirty‐five participants (64.8%) completed the entire study protocol (received a study medication and completed 14‐ and 45‐day follow‐ups). Among those who received a study medication (n = 45), 77.8% completed all follow‐up interviews. This pilot study was not designed to have sufficient statistical power for hypothesis testing, and thus, as expected, there were no significant differences between groups in medication adherence (self‐report of >80% of daily doses taken in oral group; receipt of second injection in the injection group), treatment engagement (at least treatment 3 visits in the 30 days postdischarge, and 2 or more visits per month in each of the 3 months following discharge) or alcohol consumption at 14 or at 45 days (p > 0.05). The median number of drinks among the entire cohort in the 2 weeks prior to hospitalization (128 drinks) was significantly higher than at day 14 (0 drinks, p < 0.001) or day 45 (0 drinks, p < 0.001). Rates of medication adherence were 62% in the oral group and 61% in the injection group. Conclusions: Results indicate feasibility for larger, more definitive study. Both groups had significant reductions in alcohol consumption over time and high‐treatment engagement rates. Both oral and injectable formulations are feasible to initiate prior to discharge for hospital inpatients identified as having an AUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
on behalf of the PAFS consensus group, Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., & Lancaster, G. A. (2016) · Pilot and Feasibility Studies · doi:10.1186/s40814-016-0105-8 · Cited by 2,843
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 2×
“Keeping patients engaged in treatment is desirable (McKay, 2005; McLellan et al., 2000) and is known to improve addiction-related outcomes (Blodgett et al.”
BackgroundLivingston, J. D., & Boyd, J. E. (2010) · Social Science & Medicine · doi:10.1016/j.socscimed.2010.09.030 · Cited by 1,677
The relation between different dimensions of alcohol consumption and burden of disease: an overview
Rehm, J., Baliunas, D., Borges, G. L. G., Graham, K., Irving, H., Kehoe, T., Parry, C. D., Patra, J., Popova, S., Poznyak, V., et al. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.02899.x · Cited by 1,174 · cited 2×
“High levels of alcohol consumption and AUD cause myriad disorders involving the cardiovascular, gastrointestinal (GI), hepatic, neurologic, renal, and endocrine systems (Rehm et al., 2010; Ries et al., 2014).”
BackgroundJonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 1×
“As expected, drinking decreased in both groups overall, which is in line with prior evidence indicating naltrexone’s effectiveness in reducing heavy drinking in outpatient settings (Jonas et al., 2014).”
ResultManea, L., Gilbody, S., & McMillan, D. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2014.09.009 · Cited by 795
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618 · cited 1×
“Nonadherence to daily at-home dosing has been a barrier to sustained recovery when oral preparations are used (Krystal et al., 2001; Pettinati et al., 2006; Volpicelli et al., 1997).”
BackgroundBrennan, P. L., Schutte, K. K., & Moos, R. H. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01074.x · Cited by 295
SAITZ, R. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2010.00217.x · Cited by 241 · cited 2×
“While brief advice to cut down on alcohol use has been successful in facilitating behavior change in outpatient settings, such strategies have been ineffective in the inpatient setting, likely due to the increased severity of AUDs among hospital inpatients versus the general population (Saitz, 2010; Saitz et al., 2007…”
BackgroundIs there a case for extended interventions for alcohol and drug use disorders?
McKay, J. R. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01208.x · Cited by 211
Cited by
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Oral and injectable naltrexone show similar decreases in likelihood of binge drinking [65] and both are generally well tolerated, with fairly mild side effects [66].”
BackgroundPharmacotherapy for alcohol use disorder.
Holt, S. R., & Tobin, D. G. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.008 · Cited by 17
Metadata
- Authors
- Busch, A. C., Denduluri, M., Glass, J., Hetzel, S., Gugnani, S. P., Gassman, M., Krahn, D., Deyo, B., & Brown, R.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2017-06-12
- Volume
- 41
- Issue
- 7
- Pages
- 1352-1360
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- OpenAlex
- W2625515173
- Cited by
- 26
- References
- 13
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans with Alcohol Use Disorder: A Randomized Pilot Proof‐of‐Concept Study. https://app.cochat.ai/papers/10.1111/acer.13410
- The paper
- Busch, A. C., Denduluri, M., Glass, J., Hetzel, S., Gugnani, S. P., Gassman, M., Krahn, D., Deyo, B., & Brown, R. (2017). Predischarge Injectable Versus Oral Naltrexone to Improve Postdischarge Treatment Engagement Among Hospitalized Veterans with Alcohol Use Disorder: A Randomized Pilot Proof‐of‐Concept Study. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/acer.13410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.